Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.36 |
| ▸ | F11 | P03951 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919087 | 0.84 | ROCK1 (0.36) | ROCK1LIPGF11F2PRSS1 | |
| SCHEMBL31394566 | 0.80 | LPL (0.37) | ROCK1LIPGF11LPLCA1 | |
| SCHEMBL20700302 | 0.76 | LIPG (0.38) | ROCK1LIPGF11F2PRSS1 | |
| SCHEMBL12501638 | 0.76 | F11 (0.38) | ROCK1LIPGF11F2PRSS1 | |
| SCHEMBL21198596 | 0.76 | SMN1; SMN2 (0.49) | ROCK1LIPGRAB9AALDH1A1KMT2A | |
| SCHEMBL20700304 | 0.75 | THRB (0.46) | RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL15912427 | 0.74 | RAB9A (0.48) | RAB9AALDH1A1KMT2ATSHR | |
| SCHEMBL12299346 | 0.73 | F11 (0.38) | ROCK1LIPGF11LPLHIF1A | |
| SCHEMBL17418921 | 0.73 | F11 (0.38) | ROCK1LIPGF11LPLHIF1A | |
| SCHEMBL31158040 | 0.72 | MTNR1B (0.36) | ROCK1LIPGF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | ROCK1 1820/4885LIPG 97/4885F11 1956/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | ROCK1 1820/4885LIPG 97/4885F11 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.